Hemispherx BioPharma (HEB) Short Interest Ratio & Short Volume

Short interest is the volume of Hemispherx BioPharma shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 120,600 shares of HEB short. 5.22% of Hemispherx BioPharma's shares are currently sold short. Learn More on Hemispherx BioPharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HEB shares currently have a short interest ratio of 1.0. Learn More on Hemispherx BioPharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.22% of Hemispherx BioPharma's floating shares are currently sold short.

Hemispherx BioPharma saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 120,600 shares, a decline of 9.5% from the previous total of 133,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Hemispherx BioPharma currently has issued a total of 2,442,000 shares. Some of Hemispherx BioPharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Hemispherx BioPharma currently has a public float of 2,310,000 shares.

5.22% of Hemispherx BioPharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Hemispherx BioPharma: NovaBay Pharmaceuticals, Inc. (0.58%), Eiger BioPharmaceuticals, Inc. (2.27%), Revelation Biosciences, Inc. (1.13%), Baudax Bio, Inc. (1.11%), Vyant Bio, Inc. (0.67%), Biodexa Pharmaceuticals Plc (14.70%), 180 Life Sciences Corp. (3.30%), Remedent, Inc. (0.00%), Endonovo Therapeutics, Inc. (0.00%), Virax Biolabs Group Limited (0.69%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Fred's, Inc. ($1.14 million), and Hemispherx BioPharma, Inc ($217,080.00). View all of the most shorted stocks.

Short selling HEB is an investing strategy that aims to generate trading profit from Hemispherx BioPharma as its price is falling. HEB shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Hemispherx BioPharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of HEB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HEB, twice per month. The most recent reporting period available is August, 31 2019.